

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_  
Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions: \_\_\_\_\_  
Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**Horizon NJ Health**  
***Juxtapid (Lomitapide) – Medical Necessity Request***  
***Complete pages 1 and 2 for Initial request and page 3 for Subsequent request***

**General Questions:**

**1. Contraindication Information**

- a. Is the member pregnant? **Yes or No**
  - b. Is the medication administered concomitantly with moderate or strong CYP3A4 inhibitors? **Yes or No**
  - c. Does the member have moderate or severe hepatic impairment (based on Child-Pugh category B or C)? **Yes or No**
  - d. Does the member have active liver disease, including unexplained persistent elevations of serum transaminases? **Yes or No**
2. Is medication being prescribed by or in consultation with, a cardiologist, lipid specialist or endocrinologist? **Yes or No**
3. Will the member be receiving another PCSK-9 inhibitor for the same indication? **Yes or No**
4. Will the member be on concurrent treatment with another lipid lowering therapy (e.g. statin, fibrate, nicotinic acid, ezetimibe, LDL-apheresis)? **Yes or No**  
**If Yes,** please provide the drug name(s). \_\_\_\_\_  
**If No,** why not? \_\_\_\_\_

**Diagnosis Information** (please indicate diagnosis and answer related questions):

**Homozygous familial hypercholesterolemia (HoFH)**

- a. Does member have confirmation of two mutant alleles at the LDLR, Apo-B, PCSK9, ARH adaptor protein 1 locus? **Yes or No**
- b. Does member have skin fibroblast LDL receptor activity < 20% normal? **Yes or No**
- c. What is member's untreated LDL-C level (mg/dL)? \_\_\_\_\_ Date taken: \_\_\_\_\_
- d. What is member's treated LDL-C level (mg/dL)? \_\_\_\_\_ Date taken: \_\_\_\_\_
- e. Did member have Cutaneous or tendon xanthoma before age of 10 years? **Yes or No**
- f. Does member have history of heterozygous Familial Hypercholesterolemia in both parents? **Yes or No**
- g. What is the member's total cholesterol (TC) in mg/dl? \_\_\_\_\_ Date taken: \_\_\_\_\_
- h. What is the member's non-high density lipoprotein cholesterol (non HDL-C) mg/dl? \_\_\_\_\_ Date taken: \_\_\_\_\_

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_  
Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions: \_\_\_\_\_  
Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

***Complete this page for Subsequent Request***

**General Questions:**

1. Will the member be receiving another PCSK-9 inhibitor for the same indication? **Yes or No**
2. Is medication being prescribed by or in consultation with, a cardiologist, lipid specialist or endocrinologist? **Yes or No**
3. Will the the member's liver enzymes (i.e. ALT, AST) be monitored? **Yes or No**
4. Will the member continue to receive the requested drug together with other lipid-lowering therapy (e.g. statin, ezetimibe, LDL apheresis)? **Yes or No**
  - Yes**, please provide drug name(s) \_\_\_\_\_
  - No** –Why not?: \_\_\_\_\_
5. Please provide the LDL-C, total cholesterol (TC), and/or non-high density lipoprotein-cholesterol (non HDL-C) while on therapy and date taken.

LDL: Level: \_\_\_\_\_ mg/dL                      Date Taken: \_\_\_\_\_

TC: Level: \_\_\_\_\_ mg/dL                      Date Taken: \_\_\_\_\_

Non HDL-C: Level: \_\_\_\_\_ mg/dL                      Date Taken: \_\_\_\_\_

**Physician office's signature\*** \_\_\_\_\_ **Print Name** \_\_\_\_\_

**\*Form must be completed and signed by physician or licensed representative from the physician's office**